A 5-year follow-up study of 633 cutaneous SCC excisions: Rates of local recurrence and lymph node metastasis

2018 ◽  
Vol 71 (8) ◽  
pp. 1153-1158 ◽  
Author(s):  
K. Khan ◽  
R. Mykula ◽  
R. Kerstein ◽  
N. Rabey ◽  
T. Bragg ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Local Recurrence ◽  
Node Metastasis ◽  
Follow Up Study

Radiation therapy for localised prostatic cancer: Our experience with combined radiotherapy and androgen deprivation

1996 ◽  
Vol 63 (1_suppl) ◽  
pp. 32-34
Author(s):  
S. Guazzieri ◽  
R. Bertoldin ◽  
G. D'INCà ◽  
G. De Marchi ◽  
S. Guatelli ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Median Time ◽  
Prostatic Cancer ◽  
Regional Lymph Node ◽  
Combined Treatment ◽  
Androgen Deprivation ◽  
Node Metastasis

Sixty-nine patients with localised prostatic cancer, who could not undergo radical prostatectomy due to loco-regional lymph node metastasis or anaesthesiological counter-indications, were subjected to a combined treatment, radiation therapy and androgen deprivation. All patients underwent pelvio-lymphadenectomy and those with cervico-urethral obstruction, endoscopic resection of the prostate. There was a progression of the disease in 33% of patients with lymph node metastasis (median time of progression 33 months) and in 27% of those without (median time of progression 22 months). Stable disease in 67% of patients (median follow-up over 3 years).

scholarly journals Long-Term Efficacy of Ultrasound-Guided Percutaneous Laser Ablation for Low-Risk Papillary Thyroid Microcarcinoma: A 5-Year Follow-Up Study

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Kai Peng ◽  
Ping Zhou ◽  
Wengang Liu
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Low Risk ◽  
Papillary Thyroid ◽  
Ultrasound Guided ◽  
Node Metastasis ◽  
Thyroid Microcarcinoma ◽  
Percutaneous Laser Ablation

Objective. To evaluate the long-term efficacy and safety of ultrasound-guided percutaneous laser ablation (PLA) for the treatment of low-risk papillary thyroid microcarcinoma (PTMC). Methods. From June 2012 to May 2015, 105 patients with solitary, pathologically confirmed PTMC lesions were treated with ultrasound-guided PLA. Nodule location, nodule volume, thyroid function, and clinical symptoms were evaluated before ablation. Contrast-enhanced ultrasound (CEUS) was performed 1 h after treatment to evaluate whether the ablation was complete. Ultrasound examination was performed at 1, 3, 6, and 12 months after ablation and every 6 months thereafter to determine the size of the ablation area and search for recurrence in the thyroid parenchyma and lymph node metastasis. Thyroid function was examined before and 1 month after ablation. Fine needle aspiration biopsy was performed for any suspicious metastatic lymph nodes and recurrent lesions in the thyroid. Results. All 105 lesions were completely inactivated after one ablation, making the success rate for single ablation 100%. The average ablation time was 2.78 ± 1.05  min, and the average ablation energy was 505 ± 185  J. All patients could tolerate and complete the ablation. No serious complications occurred during the treatment; only minor side effects such as pain and local discomfort were reported. The volume reduction rates were − 781.14 ± 653.29 % at 1 h posttreatment and − 268.65 ± 179.57 % , − 98.39 ± 76.58 % , 36.78 ± 30.32 % , 75.55 ± 21.81 % , 96.79 ± 10.57 % , and 100% at 1, 3, 6, 12, 18, and 24 months after ablation, respectively. This rate remained 100% at the later follow-up times. Overall, 28 (26.67%), 74 (70.48%), 96 (91.43%), and 103 (100%) were completely absorbed by 6, 12, 18, and 24 months after PLA. One patient developed another lesion 12 months after ablation, and two patients had central cervical lymph node metastasis 24 months after ablation. Conclusion. PLA is a safe and effective alternative clinical treatment for low-risk PTMC.

DNA index as a significant indicator of lymph node metastasis and local recurrence of rectal cancer

1992 ◽  
Vol 35 (12) ◽  
pp. 1130-1134 ◽  
Author(s):  
Osamu Kimura ◽  
Toshihisa Kijima ◽  
Seiji Moriwaki ◽  
Kazuyoshi Hoshino ◽  
Masao Yonekawa ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Local Recurrence ◽  
Dna Index ◽  
Node Metastasis ◽  
Recurrence Of Rectal Cancer

scholarly journals Predictors of lymph node metastasis and residual tumor in early gastric cancer patients after noncurative endoscopic resection: a systematic review and meta-analysis

2020 ◽  
Vol 13 ◽  
pp. 175628482093503
Author(s):  
Bolun Jiang ◽  
Li Zhou ◽  
Jun Lu ◽  
Yizhi Wang ◽  
Junchao Guo
Keyword(s):  
Risk Factors ◽  
Gastric Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Early Gastric Cancer ◽  
Tumor Size ◽  
Meta Analysis ◽  
Residual Tumor ◽  
Node Metastasis

Background: It is challenging to identify the prevalence of lymph node metastasis (LNM) and residual tumor in patients with early gastric cancer (EGC) who underwent noncurative endoscopic resection (ER). This present meta-analysis was aimed to establish imperative potential predictive factors in order to select the optimal treatment method. Methods: A systematic literature search of PubMed, Embase, and Cochrane Library databases was performed through 1 February 2019 to identify relevant studies, which investigated risk factors for LNM and residual tumor in patients with EGC who underwent noncurative ER. Eligible data were systematically reviewed through a meta-analysis. Results: Overall, 12 studies investigating the risk factor of LNM were included, totaling 3015 patients, 7 of which also involved cancer residues. After the present meta-analysis, six predictors, including tumor size >30 mm, tumor invasion depth (⩾500 μm from the muscularis mucosae), macroscopic appearance, undifferentiated histopathological type, positive vertical margin, and presence of lymphovascular invasion (including lymphatic invasion and vascular invasion) were significantly associated with LNM, whereas tumor size >30 mm, positive horizontal margin, and positive vertical margin were identified as significant predictors for the risk of residual tumor. No evidence of publication bias was observed. Conclusions: Six and three variables were established as significant risk factors for LNM and residual tumor in patients with EGC who underwent noncurative ER, respectively. Patients with EGC who present these risk factors after noncurative ER are strongly suggested to receive additional surgery, while others might be suitable for strict follow-up. This might shed some new light on the selection of follow-up treatment for noncurative ER.

Duodenal gangliocytic paraganglioma with lymph node metastasis and an 8-year follow-up

2012 ◽  
Vol 24 (1) ◽  
pp. 90-94 ◽  
Author(s):  
Maximilien Barret ◽  
Gabriel Rahmi ◽  
Jean-Paul Duong van Huyen ◽  
Bruno Landi ◽  
Christophe Cellier ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Gangliocytic Paraganglioma ◽  
Node Metastasis
Sign in / Sign up

Export Citation Format

Share Document